ACELYRIN News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.01.25	Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session (Benzinga)
03.01.25	What's Going On With ACELYRIN Shares Friday? (Benzinga)
12.11.24	Earnings Preview: Acelyrin (Benzinga)
18.08.24	Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out (RTTNews)
14.08.24	Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep (Benzinga)
20.03.24	Acelyrin Announces Positive Phase 1/2 Data For Lonigutamab In Thyroid Eye Disease; Stock Up (RTTNews)
11.03.24	Acelyrin's Phase2b/3 Trial Of Izokibep In Psoriatic Arthritis Meets Primary Endpoint (RTTNews)
01.01.24	ROSEN, A LEADING NATIONAL FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLRN (PR Newswire)
23.12.23	ROSEN, A LONGSTANDING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLRN (PR Newswire)
17.12.23	ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLRN (PR Newswire)
12.12.23	DiCello Levitt LLP Announces Investor Class Action Lawsuit Filed Against Acelyrin, Inc. (NASDAQ: SLRN) and Lead Plaintiff Deadline (PR Newswire)
12.12.23	ROSEN, NATIONAL INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLRN (PR Newswire)
03.12.23	ROSEN, NATIONAL TRIAL LAWYERS, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SLRN (PR Newswire)
28.11.23	MÄRKTE USA/Aktien gut behauptet - Zinsen weiter auf dem Weg nach unten (Dow Jones)
28.11.23	MÄRKTE USA/Dow & Co kommen ins Laufen - Zinsumfeld hilft (Dow Jones)
28.11.23	MÄRKTE USA/Wall Street vor Daten kaum bewegt (Dow Jones)
28.11.23	MÄRKTE USA/Wall Street vor Daten knapp im Minus gesehen (Dow Jones)
28.11.23	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Acelyrin, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2024 - (NASDAQ: SLRN) (PR Newswire)
27.11.23	Acelyrin Reveals Programming Error In Arthritis Drug Trial (RTTNews)
27.11.23	SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Acelyrin Investors of a Lead Plaintiff Deadline of January 16, 2024 (PR Newswire)
26.11.23	SLRN LOSS ALERT: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLRN (PR Newswire)
21.11.23	CLASS ACTION NOTICE: Berger Montague Advises ACELYRIN, Inc. (NASDAQ: SLRN) Investors to Inquire About a Securities Fraud Class Action (PR Newswire)
21.11.23	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Acelyrin, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2024 - (NASDAQ: SLRN) (PR Newswire)
20.11.23	SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Acelyrin Investors of a Lead Plaintiff Deadline of January 16, 2024 (PR Newswire)
17.11.23	ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLRN (PR Newswire)
12.09.23	Pre-market Movers: SLRN, SGHT, SLE, MLTX, LAW… (RTTNews)
12.09.23	ACELYRIN: Part B Of Phase 2b/3 Trial With Izokibep Fails To Meet Primary Endpoint; Stock Plummets (RTTNews)
24.08.23	Bei diesen zwei vielversprechenden Aktien hat Wall-Street-Milliardär und Citadel-CEO Ken Griffin zugegriffen (finanzen.ch) Im zweiten Quartal 2023 kaufte Ken Griffin zwei vielversprechende NASDAQ-Titel zu. Das sagen die Wall Street-Experten zu den Aktien.» mehr
09.05.23	ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	597.60	2.68 %	K V
Novartis	96.09	0.53 %	K V
Nestle	77.86	0.49 %	K V
Roche Hldg G	285.70	-0.10 %	K V
Zurich Insur Gr	553.20	-0.11 %	K V
UBS Group	31.79	-1.70 %	K V
ABB	49.03	-1.84 %	K V
Kuehne+Nagel Int	203.20	-2.12 %	K V
Sika	227.60	-2.44 %	K V
Logitech Intl	88.62	-3.13 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu ACELYRIN INC Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten